Co-Diagnostics, Inc.(CODX)

$1.08—

Ask SA Chart

Co-Diagnostics, Inc.(CODX)

NASDAQ

$1.08—

Ask SA Chart Studio

CODX(CODX)

CODX

9/23/26

Co-Diagnostics (CODX)

Wednesday

8:58 AM

ThesisRecent partnerships and regulatory approvals are expected to significantly enhance revenue potential, shifting investor sentiment positively.

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$622.5K	$654.0K	$17M
Rev. Growth	-84.1%	+5.1%	+2546%
EPS	$-35.25	$-3.10	$-0.83
EPS Growth	+5.2%	+91.2%	+73.2%
P/E	—	—	—

★ Analysts see FY2027 revenue reaching $17M — +2546% growth in a single year.

What’s Driving the Stock

01Recent partnerships with major laboratories could increase testing volumes by 50% in the next quarter.
02New regulatory approval for a rapid testing kit expected to launch in Q3 2026.
03Declining competition in the COVID-19 testing space may lead to increased market share.
04Potential for expanding product line into other infectious diseases, which could diversify revenue streams.
05Increased focus on infectious disease diagnostics post-pandemic
06Growth in personalized medicine and targeted therapies
07Changes in COVID-19 testing demand, particularly in the U.S. and Europe
08Regulatory approvals for new diagnostic tests

FY2025 Snapshot

Revenue: $622.5K
Rev. Growth: -84.1%
Gross Margin: 64.3%
Op. Margin: -5026%
Net Margin: -7534%
Net Income: $-47M
NI Growth: -24.6%
EPS: $-35.25
1Y Return: -91.8%

CODX Chart

My Notes

"The market is responding favorably to our strategic partnerships and upcoming product launches."
Moat: Co-Diagnostics' proprietary technology provides a significant barrier to entry…
growth - Investors looking for potential upside from innovative healthcare solutions.
Minimal impact as the company has low debt levels; however, higher rates could affect overall healthcare spending.
Watch on earnings: COVID-19 testing demand trends, Gross margin on diagnostic tests, Partnership agreements with healthcare providers.

One Sentence Summary:

The bull case is simple: analysts see revenue climbing from $654.0K to $17M as recent partnerships with major laboratories could increase testing volumes by 50% in the next quarter.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Strategy Focus List

Continuous multi-factor scoring & catalyst forensics

Market Movers

Today's biggest gainers and losers

Metric

FY2025

FY2026E

FY2027E

P/E

—

What’s Driving the Stock

01Recent partnerships with major laboratories could increase testing volumes by 50% in the next quarter.

02New regulatory approval for a rapid testing kit expected to launch in Q3 2026.

03Declining competition in the COVID-19 testing space may lead to increased market share.

04Potential for expanding product line into other infectious diseases, which could diversify revenue streams.

05Increased focus on infectious disease diagnostics post-pandemic

06Growth in personalized medicine and targeted therapies

07Changes in COVID-19 testing demand, particularly in the U.S. and Europe

08Regulatory approvals for new diagnostic tests

My Notes

"The market is responding favorably to our strategic partnerships and upcoming product launches."

Moat: Co-Diagnostics' proprietary technology provides a significant barrier to entry…

growth - Investors looking for potential upside from innovative healthcare solutions.

Minimal impact as the company has low debt levels; however, higher rates could affect overall healthcare spending.

Watch on earnings: COVID-19 testing demand trends, Gross margin on diagnostic tests, Partnership agreements with healthcare providers.